An arteriovenous malformation (AVM) is an abnormal tangle of blood vessels that directly connects arteries to veins, bypassing the normal capillary system. This creates high-pressure arterial shunting that weakens the vessel walls over time and can cause bleeding into the brain, seizures, and progressive neurological deficits. AVMs are typically congenital and most commonly present in young adults between the ages of 20 and 40.
AVMs are one of several vascular abnormalities of the brain that carry a risk of hemorrhagic stroke. They are related to but distinct from brain aneurysms — which can coexist with AVMs on feeding vessels — and cavernous malformations, which are lower-flow lesions with a different bleeding pattern and natural history. All three conditions are best characterized with dedicated MRI and vascular imaging.
Causes
Congenital vascular development
AVMs are believed to develop during fetal vascular morphogenesis when arteries and veins fail to form the normal intervening capillary network. Without capillaries to reduce pressure and velocity, high-pressure arterial blood flows directly into thin-walled veins that are not designed to handle arterial pressures — creating a progressively enlarging, fragile tangle of vessels prone to rupture. The majority of AVMs occur sporadically with no hereditary link.
Hereditary conditions
Hereditary hemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu syndrome) is an autosomal dominant genetic condition associated with multiple AVMs throughout the body — including the brain, lungs, and liver. Patients with known HHT and their first-degree relatives require systematic MRI screening for intracranial AVMs. Brain AVMs in HHT patients tend to be smaller and more numerous than sporadic AVMs.
Symptoms
AVMs may be entirely asymptomatic and discovered incidentally on MRI performed for unrelated reasons such as headaches. When symptomatic, the most common presentations include:
- Intracranial hemorrhage: The most dramatic and dangerous presentation — sudden severe headache, focal neurological deficits, and altered consciousness. The annual hemorrhage risk from an untreated AVM is approximately 2–4%, and the risk is higher following a first bleed.
- Seizures: A common presenting symptom, particularly for cortical AVMs — caused by irritation of surrounding brain tissue by the abnormal vasculature and hemosiderin deposition from micro-hemorrhages.
- Progressive neurological deficits: Weakness, numbness, visual disturbances, or cognitive changes caused by vascular steal — the AVM preferentially diverts blood from surrounding normal brain tissue, causing chronic ischemia in adjacent areas.
- Headaches: Non-specific headaches are common in patients with AVMs, though the mechanism is not fully established.
Diagnosis
MRI with gadolinium contrast is the primary diagnostic and surveillance tool, identifying the AVM nidus as a tangle of flow voids on standard sequences, delineating surrounding brain involvement, and detecting evidence of prior micro-hemorrhage through hemosiderin deposits visible on susceptibility-weighted imaging (SWI). MR angiography (MRA) provides non-invasive vascular mapping of feeding arteries and draining veins. CT angiography (CTA) is the first-line study in acute hemorrhage when MRI is not immediately available.
Digital subtraction angiography (DSA) — catheter-based cerebral angiography — remains the gold standard for complete AVM characterization. DSA provides real-time, dynamic visualization of the arterial feeders, nidus architecture, and venous drainage pattern — including the critical identification of intranidal aneurysms (aneurysms within the AVM itself, which dramatically increase hemorrhage risk) and high-risk drainage features such as deep venous drainage or venous stenosis. This detail is essential for Spetzler-Martin grading and treatment planning.
AVM Grading
The Spetzler-Martin grading scale (Grade I–V) quantifies surgical risk based on three factors: AVM size, eloquence of adjacent brain (whether the AVM is in or near critical functional areas), and pattern of venous drainage.
- Grade I–II: Small AVMs in non-eloquent areas with superficial venous drainage — lowest surgical risk, most amenable to curative resection with excellent outcomes.
- Grade III: Intermediate characteristics — treatment decisions individualized; surgery, radiosurgery, or combined approaches may be appropriate.
- Grade IV–V: Large AVMs in eloquent cortex or deep brain structures with deep venous drainage — highest surgical risk; radiosurgery or observation is typically preferred over surgery.
Treatments
Treatment aims to permanently eliminate the AVM to prevent future hemorrhage while preserving neurological function. The optimal approach depends on AVM size, location, grade, hemorrhage history, and patient age. A multidisciplinary team including neurosurgery, interventional neuroradiology, and radiation oncology is essential for treatment planning — particularly for complex, high-grade AVMs.
Microsurgical resection:
Complete surgical removal is immediately curative — once the AVM is fully resected, hemorrhage risk is eliminated. Surgery is preferred for accessible Grade I–II AVMs where the expected surgical morbidity is low. It provides the advantage of immediate protection from hemorrhage, unlike radiosurgery which requires years to achieve obliteration.
Stereotactic radiosurgery (Gamma Knife or CyberKnife):
Focused radiation delivered to the AVM nidus causes progressive endothelial injury and vessel obliteration over 2–3 years. It is most effective for small to medium AVMs (under 3cm) located in deep or eloquent regions where surgery carries unacceptable risk. Obliteration rates of 80–90% are achieved for appropriately selected small AVMs. The critical limitation is that hemorrhage risk persists during the 2–3 year obliteration period.
Endovascular embolization:
Catheter-based injection of embolic materials into AVM feeding vessels reduces blood flow, nidus size, and surgical complexity. Embolization is rarely curative as a standalone treatment but is widely used as an adjunct to surgery (reducing intraoperative blood loss) or radiosurgery (reducing nidus volume to improve obliteration rates). Targeted embolization of intranidal aneurysms can reduce hemorrhage risk in high-risk patients awaiting definitive treatment.
Observation:
Selected high-grade, asymptomatic AVMs — particularly in older patients or those with significant comorbidities — may be managed conservatively when treatment risk exceeds the natural history hemorrhage risk. The ARUBA trial suggested that in unruptured AVMs, medical management alone may have better short-term outcomes than intervention for some patients, though this remains an area of active debate and individualized decision-making.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Brain MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.